Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-TCR T cells for relapsed AML post-HCT
NCT01640301Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2012
- Primary completion
- Mar 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EBV-specific TTCR-C4 in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Dec 2012; status: terminated.
02
Drugs
EBV-specific TTCR-C4
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01640301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640301.